ASO Author Reflections: Which HIPEC Regimens Should be Used in Patients with Epithelial Ovarian Cancer? In the Clinic and in Randomized Trials
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Surgery
Link
https://link.springer.com/content/pdf/10.1245/s10434-023-13981-8.pdf
Reference5 articles.
1. Bhatt A, Glehen O. Hyperthermic intraperitoneal chemotherapy in the treatment armamentarium of epithelial ovarian cancer: time to end the dichotomy. Visc Med. 2022;38(2):109–19. https://doi.org/10.1159/000521239. (PMID: 35614893; PMCID: PMC9082174).
2. Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY. HIPEC for ovarian cancer collaborators. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374–83. https://doi.org/10.1001/jamasurg.2022.0143. (PMID: 35262624; PMCID: PMC8908225).
3. Bhatt A, Glehen O, Zivanovic O, Brennan D, Nadeau C, Van Driel W, Bakrin N. The 2022 PSOGI international consensus on HIPEC regimens for peritoneal malignancies: epithelial ovarian cancer. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13932-3.
4. Kim JH, Chun SY, Lee DE, Woo YH, Chang SJ, Park SY, Chang YJ, Lim MC. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01). Gynecol Oncol. 2023;170:19–24. https://doi.org/10.1016/j.ygyno.2022.12.021. (Epub 2023 Jan 4 PMID: 36608383).
5. You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, et al. Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study. J Clin Oncol. 2022;40(34):3965–74. https://doi.org/10.1200/JCO.22.01207. (PMID: 36252167; PMCID: PMC9746742).
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3